OncLive TV

Siamak Daneshmand, MD, discusses the rationale for investigating erdafitinib in patients with recurrent, intermediate-risk non–muscle invasive bladder cancer harboring FGFR3 or FGFR2 alterations.

Christopher W. Ryan, MD, discusses the implications of updated findings from the phase 3 JAVELIN Bladder 100 trial in patients with locally advanced or metastatic urothelial cancer.

Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.

Heather Lynn McArthur, MD, MPH, discusses key factors considered in the optimal sequencing of first and second line treatment option in patients with advanced triple-negative breast cancer.

Khaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.

Liat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.

Sarah Ackroyd, MD, MPH, discusses the rationale and key results from a study of time-related treatment burden in patients receiving treatment for advanced, recurrent endometrial cancer.

Beryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.

Jung-Yun Lee, MD, PhD, discusses primary efficacy and safety findings from the phase 2 KGOG3046/TRU-D trial in patients with newly diagnosed ovarian cancer.

Brian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.

Andrew Kin, MD, discusses the limitations and unmet needs associated with the use of BCMA-targeted therapies in relapsed/refractory multiple myeloma.

Nathalie McDowell Johnson, MD, FACS, discusses the accuracy of genomic testing in Black women with estrogen receptor-positive breast cancer.

Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.

Ursula A. Matulonis, MD, discusses common toxicities associated with mirvetuximab soravtansine-gynx, and how to properly manage these treatment-related adverse effects for patients with folate receptor alpha-high ovarian cancer.

Cara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.

William M. Sikov, MD, discusses the benefit of CDK4/6 inhibitors in the treatment of hormone receptor–positive/HER2-negative breast cancers.

Pannaga G. Malalur, MBBS, discusses the implications of the findings for the use of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma.

Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.

Dimitrios Nasioudis, MD, discusses how the use of next-generation sequencing can help identify the unique molecular profile of endometroid ovarian cancer.

Lindsey K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.

Brian M. Slomovitz, MD, discusses the evaluation of letrozole and ribociclib from the phase 2 GOG 3026 trial in recurrent low-grade serous ovarian carcinoma.

Shannon N. Westin, MD, MPH, FACOG, discusses the outcomes of the phase 1b SOLAR trial, which examined olaparib with selumetinib in patients with RAS-mutant gynecologic malignancies and other solid tumors.

Pamela T. Soliman, MD, MPH, discusses the use of circulating tumor DNA a clinical trial end point in endometrial cancer.

Martin F. Dietrich, MD, PhD, discusses how mutational profiling can inform subsequent treatment selection for patients with non–small cell lung cancer.

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.

Alaa Muslimani, MD, discusses the unmet needs for patients with HER2-positve metastatic colorectal cancer and highlights the implications of the phase 2 MOUNTAINEER trial in this patient population.

Alexandra Sokolova, MD,discusses the evaluation of rucaparib vs physician’s choice standard of care therapy in patients with BRCA-positive metastatic castration-resistant prostate cancer.

Andrew Kin, MD, discusses the withdrawal of the United States marketing authorization of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.